Validation of copy number variation analysis for next-generation sequencing diagnostics by Ellingford, JM et al.
1 
 
Research Article 
 
Validation of copy number variation analysis for next-
generation sequencing diagnostics 
 
Jamie M Ellingford1,2,  
Christopher Campbell1, 
Stephanie Barton1, 
Sanjeev Bhaskar1, 
Saurabh Gupta3, 
Rachel L Taylor1,2, 
Panagiotis I Sergouniotis1, 
Bradley Horn1, 
Janine A Lamb4, 
Michel Michaelides5,6, 
Andrew R Webster5,6, 
William G Newman1,2, 
Binay Panda3, 
Simon C Ramsden1, 
Graeme CM Black1,2 
 
1Manchester Centre for Genomic Medicine, Central Manchester University 
Hospitals NHS Foundation Trust, Manchester Academic Health Sciences Centre, 
St Mary's Hospital, Manchester M13 9WL, UK. 
2Institute of Human Development, University of Manchester, Oxford Road, 
Manchester, M13 9WL, UK. 
3Ganit Labs, Bio-IT Centre, Institute of Bioinformatics and Applied 
Biotechnology, Bangalore, 560100, India. 
4Institute of Population Health, University of Manchester, Oxford Road, 
Manchester, M13 9PT, UK. 
5Moorfields Eye Hospital NHS Foundation Trust, London, EC1V 2PD, UK 
6UCL Institute of Ophthalmology, Department of Genetics, London, EC1V 9EL, UK. 
 
Corresponding Author: Jamie M Ellingford, 
Jamie.ellingford@postgrad.manchester.ac.uk, +44 161 276 8703. 
 
Conflict of Interest: The authors declare no conflict of interest. 
 
Running Title: CNV detection in targeted NGS diagnostics  
2 
 
Abstract 
Although a common cause of disease, copy number variants (CNVs) have not 
routinely been identified from next-generation sequencing (NGS) data in a clinical 
context. This study aimed to examine the sensitivity, and specificity of a widely 
used software package, ExomeDepth, to identify CNVs from targeted NGS datasets. 
We benchmarked the accuracy of CNV detection using ExomeDepth v1.1.16 
applied to targeted NGS datasets, through comparison to CNV events detected 
through whole genome sequencing (WGS) for 25 individuals, and determined the 
sensitivity and specificity of ExomeDepth applied to these targeted NGS datasets 
to be 100% and 99.8%, respectively. To define quality assurance metrics for CNV 
surveillance through ExomeDepth, we undertook simulation of single exon 
(n=1000) and multiple-exon heterozygous deletion events (n=1749), determining 
a sensitivity of 97% (n=2749). We identified that the extent of sequencing 
coverage, the inter- and intra-sample variability in the depth of sequencing 
coverage, and the composition of analysis regions are all important determinants 
of successful CNV surveillance through ExomeDepth. We then applied these 
quality assurance metrics during CNV surveillance for 140 individuals across 12 
distinct clinical areas, encompassing over 500 potential rare disease diagnoses. All 
140 individuals lacked molecular diagnoses after routine clinical NGS testing, and 
through application of ExomeDepth we identified 17 CNVs contributing to the 
cause of a Mendelian disorder. Our findings support the integration of CNV 
detection using ExomeDepth v1.1.16 with routine targeted NGS diagnostic 
services for Mendelian disorders. Implementation of this strategy increases 
diagnostic yields and enhances clinical care.   
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Introduction 
Molecular diagnostic services available for patients with genetically 
heterogeneous Mendelian disease have been transformed by the adoption of next-
generation DNA sequencing (NGS) within the clinical setting.1, 2 At present, 
diagnostic services facilitated by NGS are frequently limited to targeted capture 
techniques, including custom gene panels3, 4 and whole exome sequencing (WES).5, 
6 These techniques have demonstrated tremendous power to identify rare and 
private single nucleotide variation and small insertions/deletions underpinning 
disease onset.  
The identification of large structural variants and copy number variants (CNVs) 
encapsulating the regions targeted by WES and custom gene panel assays have 
proved challenging in a clinical context. While whole genome sequencing (WGS) 
techniques have the potential to address this gap in diagnostic NGS services,7, 8 the 
cost and data burdens remain substantial. Consequently, the application of CNV 
detection algorithms in targeted NGS diagnostic services can facilitate immediate 
improvement in clinical care for individuals with heterogeneous Mendelian 
disorders. However, such techniques require formal assessment to demonstrate 
accuracy, reliability and repeatability. 
Here, we assess a framework for the implementation of CNV detection with 
targeted NGS diagnostic services applied across a range of highly heterogeneous 
Mendelian disorders.   
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Methods 
Study Design 
High coverage targeted NGS data was generated in a United Kingdom Accredited 
Clinical Laboratory. We applied a CNV detection algorithm to validate the 
sensitivity for (i) known CNV events, and (ii) simulated CNV events (Figure 1). We 
assessed a number of factors to determine whether they influenced successful 
CNV surveillance. We selected two key factors identified from assessments of 
simulated and known CNVs (inter-sample variability and insufficient coverage) as 
quality assurance metrics during prospective CNV detection for individuals 
without molecular diagnoses through clinical NGS testing (Figure 1). 
Our analyses included individuals referred for diagnostic testing for four highly 
heterogeneous disorders where targeted gene panel NGS is a routine diagnostic 
service, specifically: inherited retinal dystrophies (IRD), congenital cataracts, 
cardiac disorders and metabolic disorders. 
Sequencing & Variant Analysis 
Whole Genome and Targeted Next-Generation Sequencing 
WGS data was generated for 25 individuals by Complete Genomics (Mountain 
View, CA, USA) using a mate-paired sequencing technique, as described 
previously.9 Read alignment and variant calling was performed using version 2.5 
of the Complete Genomics pipeline.10  
For targeted NGS, enrichments were performed on DNA extracted from peripheral 
blood using Agilent SureSelect Custom Design target-enrichment kits (Agilent, 
Santa Clara, CA, USA). Enrichment kits were designed to capture known 
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pathogenic intronic variants and the protein-coding regions +/-50 nucleotides of 
selected NCBI RefSeq transcripts; conditions tested included IRD (105 genes or 
180 genes), congenital cataracts (114 genes), cardiac disorders (72 genes 
comprised of 10 sub-panels) and metabolic disorders (226 genes comprised of 6 
sub-panels). The genes and transcripts included in the targeted capture regions 
for each disease referral are available online (Supp Tables S1-S4) and through the 
UK Genetic Testing Network (http://ukgtn.nhs.uk/find-a-test/search-by-
laboratory/laboratory/manchester-rgc-36/). Samples were pooled and paired-
end NGS was performed using the manufacturer protocols for the Illumina HiSeq 
2000/2500 platform (Illumina, Inc., San Diego, CA, USA). Sequencing reads were 
demultiplexed with CASAVA v.1.8.2. and aligned to the hg19 reference genome 
using Burrows-Wheeler Aligner short read (BWA-short v0.6.2) software11 before 
duplicate reads were removed using samtools v0.1.18. 10.3 million unique NGS 
reads were generated, on average, per sample (n=170, min=1,241,785, 
max=23,240,481, median=10,812,279), with an average coverage of 880 unique 
reads per nucleotide (n=70,514,012, min=0, max=7956, median=783, sd=515.4) 
and 2155 unique reads per exon (n=388,974, min=0, max=317678, median=1561, 
sd=3309.8) within the complete region enriched for analysis. The detection and 
clinical analysis of single nucleotide variants and small insertions/deletions was 
performed as described previously.4, 12 
Copy Number Variant Detection 
For the 25 samples with WGS data, CNVs were identified using version 2.5 of the 
Complete Genomics pipeline.10 Briefly, this strategy incorporates an assessment 
of (i) sequencing read depth, and (ii) discordant mate-pairs. For each tested 
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individual, sequencing read depth was normalized for GC content and genomic 
positional effects, and CNV status was calculated for non-overlapping 2Kb 
genomic intervals through comparison to a baseline sample set – comprised of 52 
unrelated individuals. To identify the location of breakpoints and insertion points 
of CNV events, genomic regions where mate-pairs aligned to the reference genome 
displayed abnormal genomic intervals between the two reads were flagged. 
Within these flagged regions, local de-novo assembly was then performed for 
sequencing reads where only one of the two reads within the mate-pair aligned to 
the reference genome. Where possible, the genomic location of breakpoints and 
insertion points was identified and reported.  
For targeted NGS samples, CNV detection was performed using ExomeDepth 
v1.1.6.13 For each tested individual, the ExomeDepth algorithm builds the most 
suitable reference set from the BAM files of a presented group of potential 
reference samples. We presented ExomeDepth with BAM files for >20 individuals 
that had been generated by identical laboratory and computational procedures. 
All potential reference samples were individuals referred for genomic diagnostic 
testing who were not knowingly related to the tested individual, and had been 
obtained from the same sequencing run on the Illumina HiSeq platform, where 
possible. The reference sample sets selected by ExomeDepth are referred to as 
‘reference samples’ herein.  
Accuracy of ExomeDepth in comparison to WGS and MLPA 
For 25 individuals with IRD we generated gene panel NGS and WGS datasets 
(Figure 1). We used the variant detection techniques applied to the WGS datasets 
as a reference standard for CNV detection and then assessed, at the exon level 
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(n=1590 exons per sample), the sensitivity and specificity of ExomeDepth applied 
to gene panel NGS datasets. We defined sensitivity as the capability of 
ExomeDepth to identify exons with abnormal CNV, and specificity as the capability 
to identify exons with a normal CNV status. For a further five individuals with 
cardiac disorders we generated gene panel NGS and MLPA datasets (Figure 1) and 
then assessed the sensitivity of ExomeDepth applied to gene panel NGS datasets 
for these individuals.  
 
Assessment of ExomeDepth to identify simulated CNV events 
Simulated CNV events were introduced into targeted NGS data for the 25 IRD 
patients with complementary WGS data. The enrichment region for targeted NGS 
for the 25 samples encapsulates 1590 protein-coding exons for 105 genes 
associated with IRD. Importantly, we had previously defined and reported the 
copy number status for each exon included within the targeted enrichment 
through the analysis of WGS data.7 
Simulation was performed using a random sample and exon selector, bedtools 
v2.16.2 intersect, and software within the PicardTools v1.75 java package: 
DownsampleSam and MergeSamFiles (Supp Figure S1). Exons were excluded 
from analysis if they overlapped with known heterozygous deletion events in the 
selected sample. We simulated deletion events for 1000 single exons and 1749 
multiple exons (2, 3 and 4 exon events). In all cases, we assume that the intronic 
breakpoints of the deletion event are not captured through NGS. Deletion events 
are not expected to be detected above a test:reference sample read ratio of 0.7 
(see supplemental results and methods). We created three discrete groups for 
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simulated deletion events, with the extent of sequencing reads randomly removed 
indicated in parentheses: (i) control events (0%), (ii) deletion with amplification 
bias (40%) and (iii) deletion without amplification bias (50%). Further details on 
the simulation methodology are provided in the supplemental results and 
methods. 
Assessment of factors influencing successful identification of CNV events 
We assessed a number of criteria for known and simulated CNV events in order to 
assess whether they are key determinants of successful CNV surveillance through 
ExomeDepth, including:  (i) the intra-sample variation in coverage, using the 
normalized read count (reads-per-kilobase-per-million, rpkm) coefficient of 
variation (CV) for surveyed genes in test samples (Supp Figure S2), (ii) the inter-
sample variation in coverage, using the rpkmCV for surveyed exons across 
reference samples selected by ExomeDepth (Supp Figure S2), (iii) the percentage 
of nucleotides and the number of exons containing nucleotides with appropriate 
sequencing depth for in-house diagnostic surveillance (>50x unique sequencing 
reads), (iv) the total and normalized read depth across surveyed exons, (v) the GC 
content of the surveyed regions, (vi) the size of exons, and (vii) the distance 
between neighbouring exons. All statistical analyses were performed in R v3.2.1 
software. 
Integration of CNV detection during clinical NGS testing 
We integrated CNV detection using ExomeDepth into the NGS workflow for 140 
individuals from 12 distinct referral groups (Supp Table S5). The reasons for 
assessment of CNV events were (i) an assessment of whether a heterozygous CNV 
event was in-trans to a clearly or likely pathogenic variant, or (ii) an assessment 
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of whether a heterozygous CNV event was present in a gene highly specific to an 
individual’s clinical presentation. In accordance with the recommendations of the 
ExomeDepth developers, test samples with an overall correlation to selected 
reference samples <0.97 were repeated with an alternative set of reference 
samples or excluded from analysis. Clinical interpretation of CNVs was restricted 
to genes relevant to their referral on a case-by-case basis. We performed 
additional assays to confirm the presence of all identified CNVs before they were 
clinically reported. Where kits designed and created by MRC-Holland 
(Amsterdam, Netherlands) were available, we carried out multiplex ligation-
dependent probe amplification (MLPA) assays. In the absence of a suitable MLPA 
kit, we validated CNVs using droplet digital PCR or a bespoke multiplex 
quantitative fluorescence methodology (see Supplemental Methods). Validated 
CNV events were submitted to the ClinVar database.14  
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Results 
Accuracy of ExomeDepth in comparison to WGS and MLPA 
To establish the accuracy and reliability of ExomeDepth when applied to targeted 
NGS data, we analysed targeted NGS datasets for 30 individuals in whom CNV 
detection had been performed using either WGS (n=25) or MLPA (n=5).  This 
allowed calculation of the sensitivity and specificity for identified deletions and 
duplications. Overall, we found a sensitivity of 92.9% and identified that variable 
and insufficient coverage within surveyed genes reduces the capability of 
ExomeDepth to identify single exon deletions. 
In comparison to WGS, we determined that ExomeDepth applied to targeted NGS 
datasets (encompassing 1590 exons from 105 genes) has a sensitivity of 100% 
and a specificity of 99.8% (Supp Table S6) at the exon level. True positive events 
included a single exon deletion in GPR98, a 2 exon deletion in USH2A, and a 6 exon 
deletion in PCDH15 (Supp Table S7). In comparison to MLPA, we identified 3 out 
of 4 single exon deletions and one single exon duplication (Supp Table S7). We 
assessed a number of key factors, and observed that the sequencing data for the 
individual in whom a single exon deletion was erroneously not identified, showed 
the highest intra-sample variation (62%) and the highest level of  insufficient 
coverage (9.5% of exons and 0.86% of nucleotides; sample 14011718, Supp Table 
S8).  
We assessed metrics calculated by ExomeDepth for the 8 previously identified 
deletions and duplication events, observing that the average confidence (Bayes 
factor, BF) determined by ExomeDepth for true positive CNV events was 45.04 
(Supp. Table S7, min=6.4, max=76.8) and the average ratio of sequencing reads 
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between test and reference samples for deletions was 0.61 (Supp. Table S7, 
min=0.539, max=0.745) and 1.4 for the sole duplication event.  
Capability of ExomeDepth to identify simulated CNV events 
In order to assess factors that influence the successful identification of CNV events 
in targeted NGS data using ExomeDepth, we introduced simulated events, in-silico, 
into the targeted NGS datasets created in a clinical setting for the 25 individuals 
for whom we held complementary WGS data. We found a 97% sensitivity for 
simulated events when 50% of the NGS reads were removed from selected exons 
(n=2749), and identified that inter-sample variation – a measure of consistency of 
NGS read coverage across reference samples (Supp Figure S2) – and insufficient 
coverage were key determinants of whether simulated events were missed or 
identified by ExomeDepth (Tables 1 & S9). 
Single exon deletions (n=1000) were introduced into 101 of 105 genes enriched 
during NGS and we observed that the sensitivity of ExomeDepth for simulated 
events was 93.5%, with 930 deletions precisely detected at the exon level and 5 
included in deletion events erroneously identified as spanning to adjacent exons. 
This sensitivity is reduced to 79.5% when accounting for amplification bias in 
simulated events (Supp Tables S10 & S11), with an additional 140 false negative 
events identified when only 40% of the original NGS reads were removed from the 
selected exon. Interestingly, 51% (36/70) of the false negative simulated events 
without amplication bias (50% of NGS reads removed) were exons flanked by 
neighbouring exons within 250 nucleotides of the canonical donor or acceptor 
sites. Further, all of these 36 events could be identified if the neighbouring exon 
boundaries were merged into a single analysis region for simulations, increasing 
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the overall sensitivity of ExomeDepth for simulated events to 97.1% (Supp Table 
S11).  
Multiple exon deletions (n=1749) – where 50% of the NGS reads were randomly 
removed from adjacent exons – were introduced into all of the 105 genes enriched 
during targeted NGS for all 25 individuals. We observed sensitivity rates of 96.6% 
(n=620), 95.9% (n=586) and 97.1% (n=543) for 2 exon, 3 exon and 4 exon 
deletions, respectively.  
To ensure that the process of introducing simulated events into targeted NGS data 
did not influence the performance of ExomeDepth, we performed the same 
computational processes of the simulation technique for each event, without 
removing any NGS reads. No single exon or multiple exon simulated deletion 
events were identified by ExomeDepth in any of these control simulation 
experiments.  
Integration of CNV detection during clinical NGS testing 
Following assessment of the accuracy and the reliability of ExomeDepth applied 
to targeted NGS datasets, we then integrated CNV detection using ExomeDepth 
into the NGS workflow for 140 individuals from 12 distinct referral groups to 
assess specific clinical evaluations. These included either (i) an assessment of 
whether a heterozygous CNV event was in-trans to a clearly or likely pathogenic 
variant, or (ii) an assessment of whether a heterozygous CNV event was present 
in a gene highly specific to an individual’s clinical presentation. This analysis 
strategy led to the surveillance of a single gene for 128 individuals, two genes for 
10 individuals and three genes for 2 individuals.  
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Confirmation of molecular diagnoses for 17 individuals 
Analysis on a gene-by-patient basis identified 17 heterozygous CNV events (15 
deletions, 1 duplication and 1 complex event; Supp Table S12; Supp Figure S3). All 
events were verified through an alternative technique, were concluded to 
contribute to the molecular diagnosis for referred individuals and have been 
submitted to the ClinVar database (Submission number: SUB2171211). The 
heterozygous CNV events identified by ExomeDepth ranged from a 20 exon 
deletion in PCDH15 (NG_009191.2, NM_001142770.1; >600Kb) to single exon 
deletions in RPGRIP1 (NG_008933.1, NM_020366.3), BEST1 (NG_009033.1, 
NM_004183.3) and NMNAT1 (NG_032954.1, NM_022787.3). For a single individual 
referred with a provisional clinical diagnosis of Marfan syndrome, we identified a 
complex event in FBN1 (NG_008805.2, NM_000138.4): a 3-exon deletion 
(chr15:48737523-48741140, c.(5545+1_5546-1)_(5917+1_5918-1)del) and a 2-
exon duplication (chr15:48720493-48723049, c.(6739+1_6740-
1)_(6997+1_6998-1)dup), consistent with a clinical diagnosis of Marfan syndrome 
(Figure 2).  
We assessed metrics calculated by ExomeDepth for identified deletion and 
duplication events, observing that the average confidence score (BF) attributed to 
identified CNV events by the ExomeDepth algorithm was 87 (Supp Table S12, 
min=22, max=321) and the average read count ratio between test and selected 
reference samples was 0.56 (min=0.518, max=0.637) and 1.35 (min=1.31, 
max=1.38), respectively.  
15 
 
Accuracy of ExomeDepth applied in a clinical context 
To estimate the accuracy of ExomeDepth applied to targeted NGS datasets for the 
123 individuals determined to be absent of CNV events, we assessed (i) copy 
number variant status through orthogonal techniques, and (ii) two key factors 
identified through assessments of simulated and known CNV variants: inter-
sample variation and insufficient coverage (Table 1).   
We calculated the sequencing coverage for each individual, and identified that 3% 
(135/4551) of the surveyed exons contained at least one nucleotide with less than 
50 unique NGS reads. Nine of these exons were found in individuals with a 
confirmed CNV event in the gene, and 28 were in a gene confirmed to be absent of 
a CNV event through orthogonal techniques (MLPA; Supp Figure S4). Of the 
remaining 97 exons, 34 were unique patient-exon combinations and 63 were 
accounted for by 12 exons with insufficient coverage across multiple samples. On 
average, 4.6% of the nucleotides within these 97 poor coverage exons received 
less than 50 unique NGS reads (n=97, min=0.1%, max=40.9%, median=3.6%), and 
all exons were within the range of insufficient coverage values observed for true 
positive simulated deletion events (Table 1).  
To estimate the accuracy of ExomeDepth in relation to reference samples, we 
calculated the variability of sequencing coverage across the selected references 
for each individual, and identified an average inter-sample variation for surveyed 
exons of 5.1% (n=4551, sd=3.4%), with average minimum and maximum values 
observed per-individual of 2.4% (sd=1.9%) and 9.9% (sd=5.5%), respectively. In 
comparison to simulated single exon deletions, these data are consistent with an 
average sensitivity of 98.7% (sd=1.5%, min=88.7%, max=100%; Figure 3).  
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For 6 individuals, data from MLPA analyses provided additional support for the 
absence of a CNV event (Supp Figure S4). For a single individual, we identified a 
false negative event after subsequent MLPA analysis of the DSP gene. We found 
that alteration of the analysis region, to survey 5 sub-exonic regions enriched by 
non-overlapping probes though ExomeDepth identified a partial exon duplication 
event within the DSP gene which complemented the result from MLPA (Supp 
Figure S5).  
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Discussion 
Copy number variants (CNVs) are an important and common form of genomic variation 
in the general population,15, 16 and are implicated in many Mendelian disorders.7, 8, 17 
An ability to accurately survey for CNV events, in particular in targeted NGS datasets, 
therefore has the power to increase diagnostic yields and enhance clinical care. While 
it has already been shown that read count CNV detection algorithms can be successfully 
applied to targeted NGS data in a research context,13, 18-20 their integration within 
diagnostic services has been slower due to a lack of validation parameters. In this study, 
we have identified key factors which can facilitate the successful application of a 
widely used bioinformatics tool, ExomeDepth,13 for CNV surveillance of targeted NGS 
datasets within the clinical environment.  
 
CNV detection tools used in a diagnostic context must be able to identify deletion and 
duplication events that encapsulate single targets/exons included within the targeted 
enrichments of custom gene panel and WES techniques, which is a known limitation 
of some publically available algorithms. Since large datasets of known true positive 
single exon CNV events do not exist, we have developed and applied a  computational 
simulation technique which permits extended assessment of single exon CNV events. 
As a result, we have been able to perform an assessment of trends in large and controlled 
datasets (Table 1), We have then used real-time comparison between WGS and targeted 
NGS data to assess their applicability to real datasets. Using this combined approach 
we have shown that amplification bias within NGS assays and the distance between 
exons enriched during NGS influences the overall sensitivity of ExomeDepth (Supp 
Table S11). After accounting for these dominating factors, we have demonstrated how 
variability of sequencing coverage between and within samples, the extent of read 
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depth, the size of surveyed exons and the level of insufficient coverage are important 
determinants of successful identification of single exon deletion events through 
ExomeDepth (Table 1, Table S9 and S10). Whilst all these metrics are indicated as 
important quality assurance parameters for the accurate detection of single exon CNVs, 
they are neither completely independent nor equally applicable to real datasets on an 
individual basis. We therefore selected two key metrics for routine incorporation into 
diagnostics: insufficient coverage (test sample dependent) and inter-sample variability 
(reference sample dependent). This two-part process firstly checks for the quantity of 
sequencing coverage over exons surveyed in the tested sample, and second, assesses 
the consistency of NGS read coverage across reference samples for each surveyed 
exon. We have assimilated this information to successfully integrate surveillance of 
CNVs into the clinical bioinformatics pipeline for 140 individuals in a clinical setting, 
achieving a definitive molecular diagnosis in 17 of 140 individuals. Importantly, we 
have shown that 97.2% of the exons surveyed and determined to be absent of a CNV 
event have sufficient coverage, and none of the insufficiently covered exons lie outside 
the range of true positives identified from simulated experiments. Moreover, we have 
calculated the inter-sample variability for surveyed exons on an individual basis, and 
through comparison to simulated single exon events, estimated the accuracy of 
ExomeDepth to be 98.7% for the 123 individuals without an identified CNV (Figure 
3). Both of these quality assurance observations are supported by their integration with 
other CNV software tools21 and the absence of CNV events in 6 individuals tested 
through MLPA. 
 
Taken together, our data illustrate the utility of CNV assessments within a diagnostic 
setting using the publically available ExomeDepth software, and support the utilization 
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of quality assurance parameters in complement to CNV detection algorithms in targeted 
NGS diagnostic services. Whilst other types of software can be routinely applied to 
WGS datasets to detect CNVs at single nucleotide resolution, we expect that application 
of the approaches outlined in this study will improve the utilization of read depth CNV 
tools in diagnostic environments across heterogeneous targeted NGS gene panel 
approaches, including small and large gene panels, as described here, and WES.   
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Figure Legends 
Figure 1. Study Design. The approach taken in this study to assess the 
‘accuracy’ and ‘key factors’ influencing the accuracy of ExomeDepth applied 
to targeted next-generation sequencing datasets. The ‘key factors’ assessed 
by application of ExomeDepth to datasets with known and simulated CNVs 
are outlined in Table 1. CNV, copy number variation; WGS, whole genome 
sequencing; MLPA, multiplex ligation-dependent probe amplification; gene panel, 
next-generation sequencing data generated in a diagnostic environment after 
enrichment for a set of genes known as a cause of specific Mendelian disorders. 
 
Figure 2. FBN1 copy number variant. A complex 3-exon deletion, 
c.(5545+1_5546-1)_(5917+1_5918-1)del,  and 2-exon duplication, 
c.(6739+1_6740-1)_(6997+1_6998-1)dup event identified in FBN1 
(NG_008805.2, NM_000138.4), confirming a clinical diagnosis of Marfan syndrome 
for the referred individual. Red crosshairs, the ratio of reads between test and 
reference samples; grey bar, the 95% confidence interval of expected read ratios 
in comparison to reference samples.  
 
Figure 3. Inter-sample variation in sequencing coverage across surveyed 
exons. Simulations, the variability of sequencing coverage in selected reference 
samples for 971 identified and 29 missed single exon simulated deletions. 
Diagnostic survey, the variability of sequencing coverage in selected reference 
samples for 4551 exons surveyed for copy number variants in a diagnostic 
context. 
